-
Johnson & Johnson Stock Analysis: Mixed Performance Amid Regulatory Hurdles and Analyst Optimism
- 2025/01/11
- 再生時間： 2 分
- ポッドキャスト
-
サマリー
あらすじ・解説
Johnson & Johnson (JNJ) stock analysis as of January 11, 2025:
**Recent Stock Price and Trading Volume:**
The current stock price of Johnson & Johnson is $142.27 as of January 8, 2025, with a trading volume of 9,842,139 shares. This is higher than the 30-day average daily volume of 8.237 million shares[1][5].
**Recent News and Announcements:**
Johnson & Johnson has made several recent announcements, including the European Commission's approval of RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer[2]. Additionally, the company received U.S. FDA Priority Review designation for nipocalimab for the treatment of generalized myasthenia gravis[5].
**Major Analyst Updates and Price Target Changes:**
The consensus price target for Johnson & Johnson is $168 based on the ratings of 21 analysts, with the high being $215 issued by Cantor Fitzgerald on October 16, 2024[3]. The latest analyst rating was provided by Citigroup on December 11, 2024, with a price target of $175.00, indicating a possible 21.40% upside[3].
**Other Relevant News and Current Information:**
Johnson & Johnson has underperformed the market in the last year with a price return of -8.7%, while the SPY ETF gained +27.5%[5]. The company's recent pause in U.S. Varipulse procedures due to safety concerns has also impacted the stock price[5]. Despite these challenges, Johnson & Johnson remains one of the largest and most diverse healthcare firms globally, with a market cap of $342.59 billion[5].
**Recent Stock Price and Trading Volume:**
The current stock price of Johnson & Johnson is $142.27 as of January 8, 2025, with a trading volume of 9,842,139 shares. This is higher than the 30-day average daily volume of 8.237 million shares[1][5].
**Recent News and Announcements:**
Johnson & Johnson has made several recent announcements, including the European Commission's approval of RYBREVANT (amivantamab) in combination with LAZCLUZE (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer[2]. Additionally, the company received U.S. FDA Priority Review designation for nipocalimab for the treatment of generalized myasthenia gravis[5].
**Major Analyst Updates and Price Target Changes:**
The consensus price target for Johnson & Johnson is $168 based on the ratings of 21 analysts, with the high being $215 issued by Cantor Fitzgerald on October 16, 2024[3]. The latest analyst rating was provided by Citigroup on December 11, 2024, with a price target of $175.00, indicating a possible 21.40% upside[3].
**Other Relevant News and Current Information:**
Johnson & Johnson has underperformed the market in the last year with a price return of -8.7%, while the SPY ETF gained +27.5%[5]. The company's recent pause in U.S. Varipulse procedures due to safety concerns has also impacted the stock price[5]. Despite these challenges, Johnson & Johnson remains one of the largest and most diverse healthcare firms globally, with a market cap of $342.59 billion[5].